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Abstract—The effects of repeated high-energy shock wave (HESW) tumor administration on tumor blood 
flow (TBF) were studied in NU-1 human kidney cancer xenografts. Deuteriated water was used as a magnetic 
resonance spectroscopic detectable tracer for measuring tumor blood flow. Tumors were exposed twice to 
800 electromagnetically generated HESW, with a 24-h interval or sham exposed. No changes in TBF 
occurred after sham exposure to HESW. TBF levels 2 h after the first and second HESW application were, 
respectively, 46% and 37% lower than the mean preexposure TBF value and returned to normal levels 
within 16 h. There was statistically no difference found between the effects on tumor blood flow after the 
first and second HESW exposure. These observations are in agreement with earlier studies and provide a 
rationale to shorten the time interval between HESW monotreatments to 2 to 3 h.
Key Words: High-energy shock waves, Nuclear magnetic resonance spectroscopy, Cancer xenografts, Tumor 
blood flow.
INTRODUCTION
Experimental animal studies, using different tumor 
model systems, have shown that temporal growth sup­
pressive effects can be achieved by treating tumors 
with high-energy shock waves (HESW) (Debus et al. 
1989, 1991; Hoshi et al. 1991; Oosterhof et al. 1990b; 
Russo et al. 1985; Weiss et al. 1990). Moreover, com­
bination of HESW with chemotherapy or cytokines 
resulted in additive or synergistic antitumor effects 
(Lee et al. 1990; Oosterhof et al. 1990a, 1991). A 
number of variables that influence these antitumor ef­
fects have been identified, including tumor vasculariza­
tion, time interval between successive treatments, 
number of HESW, number o f HESW foci, tumor size 
and tumor model system (Hoshi et al. 1991; Oosterhof 
et al. 1990b; Weiss et al. 1990).
Several studies have been performed to clarify 
the mode of action o f HESW. Gamarra et al. (1993) 
demonstrated, with the use of autoradiography of iodo- 
[14C] antipyrine, a temporary reduction of the perfusion 
of A-mel-3 tumors after treatment with HESW. Using
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magnetic resonance spectroscopy (MRS) techniques 
we found a temporary impairment of tumor blood flow 
(TBF) in the NU-1 renal cancer xenograft after HESW 
application, resulting in a metabolic inactivation and 
acidification of the tumor (Smits et al. 1991, in press). 
Histological studies of this NU-1 tumor show changes 
in tumor vasculature due to HESW exposure, i.e., dis­
rupted capillaries, extravasation of erythrocytes, dis­
tended micro vessels with tightly packed erythrocytes 
and thrombi formation (Oosterhof et al. 1990a). Appar­
ently, one of the main targets of HESW is the vascular 
system (Debus et aL 1991; Gamarra et al. 1993; Hoshi 
et al. 1991; Smits et al. 1991; Smits et al. in press; 
Oosterhof et al. 1990b; Russo et al. 1987).
As mentioned above, earlier studies using differ­
ent tumor models revealed that the antitumor effects 
of HESW could be enhanced by repeated HESW tumor 
treatments and that shortening of the interval between 
subsequent HESW treatments from 24 h to 5 h leads 
to more effective tumor growth inhibition (Oosterhof 
et al. 1990b; Weiss et al. 1990). It is tempting to specu­
late that increased efficacy is associated with the extent 
and duration of the decrease of TBF after successive 
HESW exposures.
We therefore evaluated the effects of repeated 
HESW application on TBF. As in our previous MRS
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study, intratumorai injected deuteriated water (D20 )  
was used as a MRS detectable tracer for measurement 
of TBF (Smits et al. in press). This technique has 
proved to be a sensitive and reproducible method in 
the determination of TBF and perfusion (Evelhoch 
1992; Kim and Ackerman 1990; Larcombe-McDouall 
and Evelhoch 1990; Neil 1991). Moreover, since the 
MRS TBF measurement method is nondestructive and 
relatively noninvasive, it is possible to measure TBF 
in the same subject repeatedly. It is therefore an ideal 
technique to monitor changes in tumor blood flow after 
repeated HESW tumor administrations.
MATERIALS AND METHODS
Animals
Xenografts were transplanted in 6- to 8-week-old 
male BALB/c athymic mice (Bomholtgart, Ry, Den­
mark). The mice were kept in groups of 5 in PAG type 
2 cages covered with an iso cap (Iffa Credo, France) 
for sterile conditions. The mice were fed ad libitum 
with irradiated SRM-A MM food (Hope Farms, Woer- 
den, The Netherlands) and drinking water was acidified
(pH 3),
Tumors
The human renal cell carcinoma NU-1 xenograft 
was established in our laboratory by subcutaneous im­
plantation of small tumor pieces derived from a tumor 
nephrectomy specimen (Oosterhof et al. 1990a). For 
the HESW studies, tumors were implanted subcutane- 
ously as trocar pieces at the upper part of the hind 
limb. Passages 9 to 14 in vivo were used. The three 
dimensions of the tumor were determined with a preci­
sion sliding caliper by measuring the maximum diame­
ter and the diameters perpendicular to it. The tumor 
volume was calculated by the equation (1 X  w X h) X 
(7r/6). Tumors were allowed to grow to a volume of 
300 to 350 mm3 (mean 325 mm3),
HESW
HESW were generated by an experimental set up 
of the commercially available electromagnetic shock- 
wave source Lithostar Plus (Siemens AG, Erlangen, 
Germany). The physical and technical characteristics 
of this experimental shock-wave source have been de­
scribed recently (Steinbach et al. 1992). In short, the 
positive pressures range from 24 to 63 MPa, the corre­
sponding energy densities, defined as the time integral 
over the duration of a pulse, range from 0.08 to 0.6 
mJ/mm2. The main frequency of the pulse was 200 
kHz (resonance frequency of the system), but frequen­
cies up to 10 MHz are included. Negative pressures 
range from 5 to 10 MPa. The pressure rise time, defined
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compression
Fig. 1. Parameters of a focused shock wave. Pressure maxi­
mum CPmax), pressure rise time ft.), half-width time f t j  and
negative peak pressure (Pncg).
as the time for the pressure to rise from 10% to 90% 
of the value of Fmax, ranges from 30 to 120 ns. The 
half-width time, defined as the half-amplitude width 
of the initial positive pressure half cycle, is about 5 
/¿s. A graph of the pulse shape is shown in Fig. 1. 
The pulse-to-pulse variation was about 2% to 3%. The 
HESW were focused centrally on the tumors. In this 
way we ensured that, according to pressure measure­
ments, all parts of the tumors which had diameters of 
less than 8.5 mm experienced more than one third 
of the maximal pressure applied centrally. The shock 
waves were applied with a frequency of 2 Hz.
Just before HESW (sham) exposure, mice were 
anaesthetized with ketamine hydrochloride (Ketalar, 
Parke-Davis), 100 mg/kg, for a 15-min period. Mice 
were kept in fixed position in a plastic tube which was 
placed in the water bath. The tumor bearing leg was 
projected through a hole in the base of the plastic tube 
and the center of the tumor was positioned in the focal 
area through a three-dimensional positioning system. 
Sham exposure was achieved by placing the tumor in 
such a way that the focus (as determined by pressure 
measurements) did not encounter the tumor. Each 
HESW administration consisted of, in total, 800 pulses 
with an energy density of 0,47 mJ/mm2 (pulse repeti­
tion frequency of 2 Hz). All experiments were carried 
out with degassed water at 37°C. The NU-1 tumors 
were exposed twice to HESW (at T = 0 and T = 
24 h).
NMR spectroscopy
In vivo NMR spectroscopy was performed on a 
4.7-T Bruker WM-200 spectrometer as described pre­
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viously (Smits et al. 1991). The mice were anaesthe­
tized by means of a gas flow of 1.5% enflurane in a 
0 2/N20  mixture applied through a nose cone. Body 
temperature was monitored using a nonmagnetic tem­
perature probe and maintained at 37°C by a flow of 
humidified warm air. The tumors were exposed 
through a matched hole in a Faraday shield and posi­
tioned partly inside the radio-frequency (RF) coil to 
prevent any contribution of signals from surrounding 
tissue. The magnetic field homogeneity was optimized 
by using the jH NMR signal from tumor H20 . Typical 
linewidths of this signal were 0.1 to 0.2 ppm. The 
animals were spectroscopically examined 2 h before 
the first administration of HESW (T = - 2 )  and at T 
= 2, T  =  8, T  =  16, T = 26, T  =  32 and r  =  40 h.
The deuterium measurements were performed at 
a resonance frequency of 31 MHz, employing a home- 
built probe with a 1H/2H/31P triple tunable three-turn 
solenoid coil with an inner diameter of 14 mm. After 
optimizing the field homogeneity the RF probe was 
removed from the magnet. According to the results of 
Larcombe-McDouall and Eveihoch (1990), 60 to 70 
/xl PBS-D20  was injected (concentric) intratumorally 
at three different sites, using a 30-gauge microsyringe. 
During this procedure, the tumors remained in their 
original position in the RF coil. The probe was reposi­
tioned in the magnet and serial 2H NMR measurements 
were started within 70 s after injection.
Sixty-four deuterium spectra were collected in 49- 
s time blocks with 64 scans/block using a 10-/xs RF 
pulse, 2 k data points and a spectral width of 5000 Hz.
Data analysis
For each timepoint, every first and following fifth 
deuterium spectrum recorded was evaluated employing 
the NMR1 package (New Methods Research, Inc., Syr­
acuse, NY) on a Sun Sparc 330 station (Sun Microsys­
tems, Inc., Mountain View, CA). Free induction decays 
(FIDs) were Fourier transformed and the phase was 
manually corrected. Deuterium resonances were semi- 
automatically fitted to Lorentzian lineshape model 
functions. Absolute integrals of the deuterium reso­
nance were calculated and plotted as a function of time. 
The D20  clearance curves thus obtained are presumed 
to represent blood flow within the whole tumor (Lar­
combe-McDouall and Eveihoch 1990).
Clearance curves of D20  were best fitted using a
9
single compartment model. Tumor blood flow was thus 
determined using a single compartment model as de­
scribed by Kim and Ackerman (1990). In all cases, the 
deuterium residue washout could accurately be de­
scribed by:
Q(t) = Qbs + [<2(0) -  fie*] X  exp(~kt).
This equation describes the simplest first order kinetic 
“ single compartment model,” where Q(t) is the tracer 
quantity at time u Qbz is the nonzero steady-state tracer 
background, Q(0) is that at t = 0 and k is the first 
order rate constant governing tracer washout (Kim and
Ackerman 1990).
Since the steady-state tracer background (residual 
from previous experiment) has already been subtracted 
from the original decay curve the deuterium washout 
decay can be formulated as;
0 (0  =  0 (0) X exp( -& ) •
The formula TBF = 100 X lambda X k ' is then an 
estimate of the initial tumor blood flow (in units of 
milliliters per 100# X min). Here, lambda is the tumor- 
to-blood partition coefficient (ratio of the water weight 
of a unit mass of tumor to the water weight of a volume 
of blood) which was determined by measuring wet and 
dry weights of tumor and blood. Dry weights were 
achieved by drying in an oven at a temperature of 90°C 
until no changes in weight were measured. Lambda 
was calculated to be 0.906 ± 0 .0 1 9  (in units of millili­
ters per gram per hour) (n = 5).
Statistics
Because of the normal distribution pattern of the 
calculated TBF, the two-sided t test was used to com­
pare the TBF between the control and HESW applied 
group and to evaluate the effect of the second HESW 
administration. Statistical significance was set at p
<  0.05.
RESULTS
Although it is difficult to define a specific biologi­
cal active focus, and thus to define an effective treat­
ment volume, all tumor tissue was exposed to at least 
one third of the maximum positive pressure applied. 
Earlier studies have shown that this way of HESW 
tumor exposure leads to significant antitumor effects 
evaluated for tumors as a whole (Debus et al. 1989, 
1991; Hoshi et a l 1991; Lee et al. 1990; Oosterhof et 
al. 1990a, 1990b, 1991; Russo et al. 1985; Weiss et 
al. 1990).
According to the results of Larcombe-McDouall 
and Eveihoch (1989), 60 to 70 /iL D20  was injected 
intratumorally at three different sites, presuming that 
the D20  clearance curves thus obtained represent blood 
flow within the whole tumor. The D20  clearance 
curves were best fitted using a one-compartment 
model.
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Fig. 2. D20  outflow curves, with data points each five measurements, at seven different time points of a sham- 
treated control tumor obtained by 2H MRS after intratumoral injection of an isotonic D2O solution. Closed circle: 
pre-exposure; open triangle: 7 = 2 h; open circle: 7  — 8 h; cross; 7  = 16 h; closed triangle: T — 26 h; open
square: 7  = 32 h; closed square: T = 40 h.
Tumor blood flow in control tumors
In Fig. 2 seven D20  outflow curves obtained at T
= -2 ,  7  = 2, T = 8, 7  = 16, 7  = 26, 7  = 32 and 7  
= 40 h from one representative control NU-1 tumor 
are shown. Calculated mean TBF of all HESW nonex­
posed control tumors (n = 5) for tfye subsequent time 
points revealed no significant changes in TBF during 
this time period (p — 0.17, Fig. 3).
7umor blood flow in HESW-exposed tumors
The mean pre-HESW (sham) exposure TBF values 
in the HESW and control groups were not statistically
different (Fig. 3). Administration of 800 HESW on the 
center of the tumor resulted in a decrease of the mean 
TBF of 46 ± 19% after 2 h and 16 ±  30% after 16 h. 
A second HESW exposure, 24 h after the first, resulted 
in a decrease of the mean TBF with 37 ±23%  after 2 h 
and 16 ±  34% after 16 h when compared to preexposure 
values. As a result, TBF levels 2 h after the first and 
second HESW administration were significantly lower 
than the preexposure TBF (p = 0.02 and p =  0.04, 
respectively). Moreover, comparing the effect on TBF 
of the first and second HESW administration revealed 
no significant difference (p = 0.45).
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Fig. 3. Calculated mean tumor blood flow (in units of ml/100 g X  min) with SD of five sham-treated control 
tumors (gray bars) and of five HESW-treated tumors (black bars). Tumors were HESW- or sham-treated at 7 =
0 and at 7 -  24 h.
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DISCUSSION
Recently, it has been demonstrated that the vascu­
lar functionality of tumors is the primary target of 
HESW tumor therapy (Gamarra et al. 1993; Smits et 
al. in press). Exposure o f tumors to HESW causes a 
temporary decrease in TBF, resulting in a metabolic 
inactivation and acidification (Smits et al. 1991, in 
press). The modulatory effects of HESW on TBF may 
be used to overcome the limited efficacy of other treat­
ment modalities. For instance, a threefold increase of 
the intratumor concentration of systemically given tu­
mor necrosis factor alpha (TNF-a) was achieved after 
HESW tumor treatment (Cornel et al. in press). More­
over, the HESW-induced decrease of TBF may proba­
bly improve the efficacy of thermotherapy. Monitoring 
the effects on TBF of (repeated) HESW exposure(s) 
is therefore of importance to improve the efficacy of 
HESW treatments, not only as monotherapy but also 
in combination with other therapies. A 24-h time inter­
val was chosen because we wanted to investigate the 
effects of a second HESW treatment after functional 
recovery of the TBF.
Several methods can be used to measure blood 
flow and tissue perfusion, either directly or indirectly 
(Appelgren 1979). Among the methods developed to 
measure TBF indirectly, radiolabeled and MRS detect­
able tracers are most commonly used. There are several 
advantages of MRS-based methods above the use of 
radiolabeled tracers (Evelhoch 1992). First, MRS is 
nondestructive and relatively noninvasive. Second, sta­
ble isotopes (e.g., deuterium or fluorine) are used, elim­
inating problems of radiation exposure and special 
tracer handling. Finally, concurrent *H and 31P MRS 
measurements can be performed, evaluating tissue me­
tabolism. On the other hand, the main disadvantage 
of this technique is that it requires specialized and 
expensive equipment. In the present study we used the 
deuterium clearance method to calculate TBF at vari­
ous timepoints after successive HESW exposures. In 
an earlier study we demonstrated that in the NU-1 
tumor this method gives reproducible deuterium out­
flow curves after repeated intratumoral D20  injections, 
independent of the number o f injection sites (Smits et 
al. in press). The maximal mean absolute difference 
found between washout curves, obtained at time inter­
vals between 3 and 6 h for an individual tumor, was 
7% of the relative HOD intensity at t = 0 (Smits et 
al. in press). Here we demonstrate that a second HESW 
application of this NU-1 tumor results in a decrease 
in tumor blood flow which is statistically not different 
from the effect on TBF seen after the first HESW 
exposure. Both HESW exposures resulted in a signifi­
cant decrease of TBF 2 h after therapy, followed by
normalization to preexposure values within 16 h. The 
extent and duration of the decrease in TBF after the 
first HESW administration were comparable with those 
described earlier (Smits et al. in press). However, the 
absolute TBF flow values of the NU-1 tumors used in 
this study were much lower than found earlier (Smits 
et al. in press). Several reasons can be taken into con­
sideration for this major discrepancy. First, there are 
major differences in tumor doubling time between the 
early passages used now and the late passages used 
earlier (8 and 3.5 days, respectively). The lower tumor 
doubling time of these early passages of the NU-1 
tumor might well be representative of a less well-de­
veloped vascular system. Second, since the MRS sur­
face coil used in the present study was bigger than 
used in our earlier work, the tumors needed to grow 
to significantly higher volumes compared to the afore­
mentioned study. For other xenografts it has been dem­
onstrated that TBF values correlate with tumor volume, 
the bigger the tumor the lower the TBF (Lyng et a l 
1992). Finally, in contrast to our earlier study, D20  
clearance curves were best fitted using a one-compart­
ment model. For the RIF tumor it has been demon­
strated that TBF values, calculated using a monocom­
partment model, were significantly lower compared to 
the TBF values calculated from the same clearance 
curves, using a two-compartment model (Kim and 
Ackerman 1988).
Earlier studies, using different tumor models, re­
vealed that the antitumor effects of HESW could be 
enhanced by repeated HESW tumor treatments and that 
shortening of the interval between subsequent HESW 
treatments leads to more effective tumor growth inhibi­
tion (Oosterhof et al. 1990b; Weiss et al. 1990). Al­
though the exact length of the time interval remains 
debatable, this study further rationalizes the shortening 
of the time interval between HESW exposure. Reperfu­
sion of the HESW-exposed tumor cannot occur and 
the prolonged ischemia will induce more cell death. 
Denekamp et al. (1983) reported for the SA F mouse 
tumor that 15 h of ischemia was required to obtain 
local cure of the tumor. Assuming that such a long 
time period will also be necessary for other tumors, 
this would imply that five or six successive HESW 
treatments should be given to achieve sufficient isch­
emia time to provoke complete local tumor regression.
Optimalization of time schedules for HESW treat­
ment in combination with other therapies, e.g., system­
ically given drugs (chemotherapy or BRMs), based on 
this study, will be more difficult. Recently we demon­
strated that a threefold increase in the intratumor con­
centration of systemically given TNF-a: can be 
achieved after one HESW tumor treatment (Cornel et 
al. in press). Yet it is not known to what extent TBF
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must be recovered before a second treatment of HESW 
in combination with systemically given drugs would be 
effective. It is obvious that drugs need to have access to 
the tumor before the selective shutdown of the tumor 
vasculature will result in increased intratumoral drug 
levels.
In conclusion, it becomes clear that HESW are 
capable of damaging the tumor vasculature selectively. 
The reason for the discrepancy between the histologi­
cally proven vascular damage and the relatively short 
functional effects on tumor blood flow is not yet 
known. It might be possible that after HESW exposure 
a temporary (cavitation induced) increased vascular 
permeability occurs, resulting in the extravasation of 
the erythrocytes.
It is tempting to speculate that this HESW-in- 
duced decrease of tumor blood flow will be able to 
rule out problems of inadequate drug uptake and non- 
optimal distribution in the tumor. The potential of 
HESW to increase the efficacy of systemic therapies 
by selective temporary changes in TBF will possibly 
determine its clinical application.
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